A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine and Cisplatin in Patients with Metastatic or Advanced Solid Tumours

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine and Cisplatin in Patients with Metastatic or Advanced Solid Tumours

Planning
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs L-DOS 47 (Primary) ; Cisplatin; Vinorelbine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 29 Oct 2015 According to a Helix BioPharma media release, the company intends to investigate L-DOS47 in combination with Vinorelbine and Cisplatin ("VIN/CIS") in patients with metastatic or advanced solid tumours. After discussion with key advisors, the Company is considering a redesign of the LDOS003 study to focus on advanced stage lung cancer patients by combining L-DOS47 with VIN/CIS.
    • 19 May 2014 New trial record
    • 14 May 2014 Helix Biopharma has submitted a Clinical Trial Application with Health Canada for this trial, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top